肿瘤血清标记物骨桥蛋白用于诊断胰腺癌研究

Evaluation of osteopontin as serum tumor marker for pancreatic cancer

目的评价骨桥蛋白(OPN)作为肿瘤血清标记物在胰腺癌诊断中的作用。方法收集北京协和医院胰腺外科2004年2月至2006年2月相关临床住院病人的血清64例,运用ELISA法检测其中的46例胰腺癌病人、18例慢性胰腺炎病人以及20名健康人的血清中的OPN、CA19-9和CA242的含量。用ROC曲线法对检测结果进行分析,同时对结果进行统计学检验。结果三种肿瘤标记物的水平在胰腺癌组均高于慢性胰腺炎组,且差异均有显著性意义(P<0.01)。运用ROC曲线法对三种肿瘤标记物的检测结果进行处理。OPN、CA19-9和CA242的AUC(area under curve)分别为0.788、0.808和0.737。分层分析表明,OPN和CA19-9在手术无法切除组高于手术可切除组(P<0.01)。结论OPN在胰腺癌血清学诊断中有临床意义,若同时联合检测CA19-9,则对胰腺癌术前可切除性评估有一定的临床价值。

Objective To evaluate the effect of osteopontin （OPN） as serum tumor marker on the diagnosis of pancreatic cancer. Methods Used ROC （ receiver-operating characteristics ） curve methods to assay the serum content of OPN, CA19-9 and CA242 in 46 patients of the pancreatic cancer, 18 patients of the chronic pancreatitis detected by enzymelinked immunosorbent assay （ ELISA ） , and analyzed the results with statistics methods. Results The serum levels of OPN, CA19-9 and CA242 in pancreatic cancer are all higher than in chronic pancreatitis respectively （ P 〈 0. 001 ）. To treat the measure results of four serum tumor markers with ROC curve methods,The AUC （area under curve） of OPN, CA19-9 and CA242 are 0. 788,0. 808 and 0. 737 ,respectively. Subgroup analysis indicated that the OPN and CA19-9 levels for patients with resectable pancreatic cancer were lower than those for patients with unresectable pancreatic cancer （ P 〈 0. 001 ）. Condusion In diagnosis of pancreatic cancer,the clinical value of OPN is available. And the combination test of CA19-9 and OPN have clinical value to evaluate if the pancreatic cancer can be resected before operation.